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Fertility Preservation in Cancer Patients: The Global Framework  
Abstract 
Cancer treatment is the most frequent cause of reduced fertility in cancer patients, with up to 
80% of survivors affected. None of the established or experimental fertility preservation 
methods can assure parenthood; instead it may provide a future opportunity to overcome 
treatment induced sterility. Previous research demonstrated that fertility counselling has 
clinical and psychological benefit. Therefore, such patient services are recommended by 
internationally recognized guidelines. Around 70-75% of young cancer survivors in 
retrospective studies are reported to desire parenthood but the numbers of patients who use 
fertility preservation services prior treatment are significantly lower. Moreover, despite 
existing guidelines healthcare professionals worldwide lack practical knowledge and have 
personal biases which prevent addressing fertility preservation issues adequately. Surveys of 
healthcare professionals report the following barriers: lack of time and knowledge about 
existing options, poor prognosis, and delay in treatment, patient’s age, partnership status, 
existing children, sexual orientation and socioeconomic situation. Moreover, fertility 
preservation consultation is not limited to medical aspects. Patient’s fears, expectations and 
priorities shaped by personal values have to be addressed in a light of medical necessities, 
realistic survival prognosis, socio-cultural environment and availability of resources. We call 
for a need of framework for patient centred fertility counselling with a proposal that such 
framework should include support in decision making which would help patients to 
understand medical aspects of their cancer, realistic fertility preservation options, identify 
their preferences based on personal values and goals. Optional support services could also 
include legal guidance, psychological and spiritual support and financial counselling.  
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Introduction  
Cancer is predominantly associated with older age, but it also affects children, adolescents 
and young adults. Survival rates are known to be the highest for patients aged between 15 and 
44  [1], with 5-years survival ranging from 60 to 82% according to age, tumour site and 
country of treatment [1,2,3,4,5,6]. Cancer therapies, nevertheless effective, often come with 
undesirable side effects, some of which are for a lifetime. Among these, infertility may affect 
up to 80% of cancer survivors as a result of treatments [7].  
Cancer itself is rarely a direct cause of infertility [8,9]. Chemotherapy, radiotherapy or 
surgical removal of reproductive organs is the most frequent determinants of infertility in 
cancer survivors [10].  
Cancer treatment effects on fertility 
Male germ cells are sensitive to injury caused by cytotoxic drugs [11]. Leydig cells are 
resistant to chemotherapy [8], thus infertility rather than impaired sexual function altered by 
endocrine milieu is more frequently reported after oncological treatments. In females, ability 
to conceive can be affected by previous exposure to chemotherapy, radiotherapy or surgery. 
Adequate follicular reserve, a functioning hypothalamic-pituitary-ovarian axis and a normal 
uterus are all necessary for a normal pregnancy [8]. Many chemotherapeutic agents are 
gonadotoxic, but alkylating agents pose the highest risk of permanent infertility [12]. 
Moreover, oocytes are extremely sensitive to ionizing radiation, with direct correlation with 
dose and increasing patient’s age [12]. Cranial radiation, affecting the hypothalamic-pituitary 
axis, may also impair fertility [12,13].  
Established and experimental methods can be used to preserve fertility. None of them assure 
parenthood after cancer, thus unrealistic expectations or false hopes should be given to the 
patients [14]. The most established and clinically approved methods for fertility preservation 
are sperm cryopreservation for men; embryo and oocytes cryopreservation and ovarian 
transposition for women [15]. 
Fertility preservation options for male patients 
Sperm cryopreservation is the only established method for male fertility preservation [15]. 
Usually 3 semen samples are frozen, with at least 48-hours abstinence periods between each 
collection. However, if there is an urgent need to start cancer therapy, fewer samples can be 
cryopreserved [16]. As single intracytoplasmic sperm injection (ICSI) is now commonly used 
in assisted reproduction, thus allowing the successful use of samples with few spermatozoa 
[16,17]. It has been reported that 21% of Hodgkin lymphoma survivors who cryopreserved 
sperm prior their treatment used it [18] and a live birth using sperm frozen 21 years ago has 
been described [19]. In prepubertal boys, testicular tissue cryopreservation is the only 
possibility for fertility preservation. Spermatogonial diploid stem cells could possibly 
develop into mature cells after transplantation [16], but this method still remains 
experimental at the present time [20]. There is also a concern that with testicular tissue auto-
transplant the malignancy can be reseeded [21].  
Fertility preservation options for female patients 
Embryos cryopreservation is the most established and successful method for female fertility 
preservation. It requires delaying cancer treatment by 2-3 weeks and the availability of a 
partner. If a partner is not available or where embryo cryopreservation is not permitted by 
law, oocytes cryopreservation is a valid alternative [16]. Oocyte cryopreservation is not 
considered experimental since 2013, by the American Society of Clinical Oncology (ASCO) 
and the European Society of Medical Oncology (ESMO) [22,23].  More than 1000 births 
have been reported worldwide from cryopreserved oocytes [22,24]. Summary of different 
guidelines and their implications on fertility preservation practices are given in Table 1. 
Both embryo and oocyte cryopreservation need an ovarian stimulation with gonadotropins 
and oocyte harvesting. In oestrogen dependent tumours, there is concern that ovarian 
stimulation may increase disease recurrence [16]. The concomitant administration of 
Letrozole reduces oestrogen peak and disease free survival was similar in women who had 
ovarian stimulation, compared with women who did not have it [25] but available data is 
based on a few trials and short follow up periods. Ovarian transposition (also called 
oophoropexy or ovarian suspension) is the surgical translocation of ovaries from the 
irradiation field in pelvic area. This method does not protect against chemotherapy or whole-
body irradiation [16]. 
Ovarian suppression using gonadotropin-releasing hormone agonists for fertility preservation 
remain controversial. There is no sufficient evidence that it protects gonadal function from 
gonadotoxic agents [22].  
Ovarian tissue cryopreservation is laparoscopic removal of ovarian cortical tissue which is 
cryopreserved and transplanted back at the time when conception is desired [16]. Ovarian 
grafts can be transplanted back to the pelvis or subcutaneous areas for oocyte maturation 
[26]. There has not been pregnancies achieved using frozen-thawed ovarian tissue taken from 
prepubertal girls [27], possibly for the high numbers of abnormal non-growing oocytes [28]. 
Same as in testicular tissue auto-transplantation, ovarian tissue auto-transplantation can bring 
back malignancy. 
Twenty eight live pregnancies have been achieved with orthotopic ovarian tissue transplant 
from patients with haematological malignancies and breast cancer [29]. Currently about 100 
centres worldwide perform ovarian tissue cryopreservation [13]. Whole ovary 
cryopreservation is experimental method and no live births have been achieved using this 
technique. It has been reported that 2 babies were born from whole ovary transplantation in 
monozygotic twin donor [30]. Therefore, some authors suggest that cryopreservation and 
retransplantation of whole ovary is promising and further research should be encouraged 
[31]. 
Moreover, there is a group of oncology patients known as ‘previvors’ and they deserve a 
special attention in cancer treatment and fertility preservation debate. These patients have 
cancer history running in their families and are at increased risk to develop cancer early in 
their lives. They have to think about prophylactic therapies even before being diagnosed with 
cancer. Such prevention strategies are suggested for women who are BRCA1 and BRCA2 
mutation carriers and have high risk of developing breast or ovarian cancer [32]. Women of 
African ancestry under age of 45 have an elevated risk of breast cancer at young age 
compared to Caucasian women and their cancers are more aggressive that present as 
oestrogen receptor negative tumours [33]. It is suggested that these different groups of 
patients might have special needs that are unmet during fertility preservation counselling 
[34].  
Table 1 
Guidelines for fertility preservation in cancer patients 
Releasing body; 
year 
Scope Main statements regarding toxicity of cancer 
therapy, fertility preservation (FP) and future 
procreation 
Reference 
 
American 
Society for 
Reproductive 
Medicine – 
ASRM; 2013  
All cancer 
patients 
Clinicians should inform patients about FP 
options and future reproduction before 
gonadotoxic treatment begins.  
Concerns about welfare of resulting offspring 
are not sufficient reasons to deny assistance in 
reproduction. 
Parents may act to preserve fertility for 
minors (assent and likeliness to provide future 
benefit). 
PGD to avoid offspring inheriting high risk of 
cancer is acceptable. 
Patients should have access to mental health, 
genetic and financial counsellors.  
 
[35] 
American 
Society of 
Clinical 
Oncology – 
ASCO; 2013  
All cancer 
patients 
Discuss FP with all patients of reproductive 
age (with parents or guardians of children and 
adolescents). 
Refer interested (and ambivalent) patients to 
fertility specialist. 
Address FP before treatment starts. 
Document FP discussion in medical records. 
Answer basic questions about FP and its 
impact on cancer treatment. 
Refer patients to psychosocial providers if 
patients experience distress. 
Encourage patients to participate in registries 
and clinical studies. 
 
[22] 
National 
Comprehensive 
Cancer Network 
– NCCN, USA; 
Adolescents 
and Young 
Adult (15-
39) 
Fertility preservation should be an integral 
part of cancer management.  
The use of contraception should be discussed 
[36] 
2014  with all women before initiation of treatment. 
Women diagnosed with cancer during 
pregnancy require individualised treatment by 
multidisciplinary team. 
All patients should have access to age-
appropriate supportive care and medical 
subspecialty services. 
 
European 
Society of 
Medical 
Oncology – 
ESMO 
(endorsed by 
Japanese 
Society of 
Medical 
Oncology – 
JSMO); 2013 
 
 Focuses on 
pregnant 
women 
with cancer 
but has a 
section for 
post-
pubertal 
patients 
Male: sperm banking should be planned 
before treatment initiation. 
Female: Young women desiring future 
fertility should be counselled on available 
fertility preservation options before starting 
anti-cancer treatment. 
 
[23] 
European 
Society of 
Breast Cancer 
Specialists – 
EUSOMA; 
2014  
Young 
women 
(under 40) 
Fertility issues should always be discussed 
before the start of any breast cancer therapy. 
Discussion should allow time for reflection 
and involve partner, if present. 
Early referral to reproductive endocrinologist 
is warranted.  
 
[37] 
European 
Society of 
Human 
Reproduction 
and Embryology 
– ESHRE ;  
publishes ethical 
considerations 
from 2001. 
Does not 
have a 
guideline 
specifically 
for 
oncology 
patients 
Provides guidelines relevant to fertility 
preservation in oncology: cryopreservation, 
PGD, posthumous reproduction, infertility 
treatment, wellbeing of ART children, 
distinction between established and 
experimental treatment (concerning oocyte 
cryopreservation) at http://www.eshre.eu .  
 
 
What do patients think about fertility preservation and what happens in the real world? 
Retrospective surveys of cancer patients’ views suggest that the majority have a strong desire 
to be informed about fertility preservation and available options [31,38,39,40]. Moreover, 
concerns about infertility are not limited to patients who are young and childless or/and have 
a partner [41]. It has been reported that up to 70-75% of young cancer survivors would like to 
have a child [39,42] with up to 29% of women refusing life saving treatment because of fear 
to become infertile [42], including a case reports where refused therapy lead to foetal and 
maternal death [43]. However, significantly lower numbers actually proceed with fertility 
preservation procedures (Table 2). Despite proven clinical and psychological benefit [41,44] 
and recommendations that cancer patients should be routinely asked about their interest to 
preserve fertility before starting cancer treatment (Table 1),  nearly half of patients are not 
given information about the impact of cancer treatment on their future fertility (Table 2).  
Studies on patients’ attitudes and fertility preservation choices are being conducted 
worldwide. In Table 2 we summarized studies from the USA, Canada, Sweden and Germany 
which report patient attitudes and the choices they subsequently made in order to preserve 
fertility. It is important to note that patient surveys vary in a sample size, methods how 
surveys were conducted and reported response rate is often less than half of eligible 
participants which could mean that only patients who were concerned about fertility chose to 
answer the questions. Moreover, the reported sample sizes are often too small for making 
valid generalizations relevant to all cancer patients. However, these studies revealed some 
important aspects in fertility preservation practices. First, majority of cancer patients 
regardless of final decision find fertility consultations important part of their treatment 
planning. Second, there are still high numbers of patients reported who have not received any 
kind of fertility preservation consultation. This tendency seems to be apparent among female 
patients [39,45] and especially among racial minorities in the USA [34]. UK study of women 
with breast cancer who were childless concluded that although guidelines are available, many 
women were not given adequate information or offered treatments or interventions to 
preserve fertility [38]. This leads to the third point that women preserve fertility less often 
than men. 
For instance, study from Germany reports that only 40% of cancer patients who wanted 
children in the future underwent fertility preservation [39]. Results from Swedish cancer 
survivors’ survey reveal large gender disparities in received information about treatment 
impact on fertility, with 80% of male and 48% of women informed and while 54% of male 
patients banked frozen sperm, only 2% of women underwent fertility preservation [45]. There 
are only scarce data available from countries other than those in North America and Europe. 
But it is likely that fertility preservation for cancer patient issues might share a lot of 
similarities with countries already researched. For instance, in Saudi Arabia less than 20% 
male patients are referred to fertility specialist [46], which suggests that even male patients 
do not always take the full advantage of fertility preservation options.  
Another study has been published recently comparing attitudes towards fertility loss among 
young breast cancer patients. This study collected data from Western and Eastern Europe, 
South Africa, Middle East and South America concluding that 59% of patients wanted to 
have children in the future but cure was the first priority and only less than 10% would accept 
lower chances of survival to preserve fertility [47]. These numbers suggest that the 
importance of fertility could have been overestimated but some other studies show that 
having a child could have a positive effect on cancer survivors helping them to stay well, feel 
complete and look forward to the future [47]. However, even women with positive attitudes 
about having children after cancer have fears that possible pregnancy would increase chances 
for cancer recurrence or transmitting the cancer risk to the future child [47,48].  On the other 
hand patients who already have children might focus more on survival than fertility 
preservation [40,42] and as a result might be less likely to be offered fertility preservation 
consultation [46,49]. Therefore, discussing cancer treatment implications on fertility and 
possible fertility preservation options as well as providing patients with decisional support 
would significantly help to improve cancer care and benefit the patients in any country. 
Table 2 
Cancer patients’ attitudes towards fertility preservation (FP) 
Country; 
Publication 
year 
Participants; 
Type of study 
Attitudes, 
expectations, 
experiences 
regarding FP (%) 
 
Number of patients 
who used FP and 
methods (%) 
Reference 
Texas, USA; 
2012  
33 African 
American breast 
45% reported 
retrospectively 
1 patient froze [34] 
cancer survivors 
under age of 45; 
semi-structured 
phone interviews 
that they had 
wanted a child at 
the time of 
diagnosis 
48% did not 
remember having 
discussed FP 
with a doctor 
14% of those 
who had 
chemotherapy 
have been 
offered FP 
 
embryos and oocytes 
1 patient froze oocytes 
4 patients became 
pregnant after cancer 
treatment 
1 sought IVF 
treatment 
2 adopted children 
after their cancer 
USA; 2014  620 women aged 
17-40 newly 
diagnosed with 
early breast 
cancer; 
multicenter 
cohort study, 
survey by mail 
68% discussed 
fertility issues 
before starting 
the therapy 
51% were 
concerned about 
becoming 
infertile 
26% concerns 
about fertility 
affected their 
treatment 
decisions 
 
10% pursued FP 
7% embryo 
cryopreservation 
1% oocyte 
cryopreservation 
3% received 
gonadotropin-
releasing hormone 
agonist (GnRH-a) 
[50] 
Canada; 2012  27 breast cancer 
patients aged 24-
41; anonymous 
mail 
questionnaire 
56% of FP 
consultations 
were made after 
surgery before 
chemotherapy 
33%  of FP 
consultations 
were made 
56% (15 patients) 
underwent FP 
9 patients froze 
embryos 
6 froze eggs alone 
2 ovarian suppression  
 
[51] 
before surgery 
85% 
consultations 
were made 
within a week of 
referral  
 
Canada; 2012  41 female cancer 
patients aged 24-
42, majority 
breast cancer, 
others ovarian 
cancer, 
lymphoma, brain 
cancer, 
Hodgkin’s, 
carcinoma, 
leukaemia; mail 
questionnaire  
 
97,6% regardless 
of final decision 
said that it was 
important to be 
seen by 
reproductive 
specialist 
 
 
31,7% proceeded with 
IVF for 
cryopreservation (13 
patients) 
6 were planning to 
initiate pregnancy 
soon 
[41] 
Sweden; 2012  484 survivors 
aged 18-45 at 
diagnosis who 
had lymphoma, 
acute leukaemia, 
testicular cancer, 
ovarian cancer or 
female breast 
cancer treated 
with 
chemotherapy; 
postal 
questionnaire 
80% male 
patients received 
information 
about treatment 
impact on 
fertility 
68% male 
patients received 
information 
about FP 
48% female 
patients received 
information 
about treatment 
impact on 
fertility 
14% female 
patients received 
54% male patients 
banked sperm 
2% female patients 
underwent FP 
including embryo and 
oocyte 
cryopreservation, 
ovarian suppression, 
radiation shielding of 
gonads 
[45] 
  
Healthcare professionals’ attitudes towards fertility consultation in oncology patients 
It is suggested that individual plans for fertility preservation must take into account both 
patient’s priorities and medical necessities [15], especially when healthcare systems are run 
on limited resources. There is also a need to create a functional infrastructure for oncofertility 
services. However, even countries with established services for patients face problems. For 
instance, in the United States fertility preservation services are currently available to most 
patients who are under the age of 45 [32] but some still have restricted access to care due to 
their socioeconomic situation, insurance plan or geographical location [33]. Fertility centres 
in Canada are enthusiastic about working together with other healthcare providers to offer 
fertility preservation services for cancer patients [48]. However, despite all required 
components are present in the Canadian system, their coordinated functioning remains 
challenging [52].  
Despite existing fertility preservation methods for both men and women, patient wishes to be 
informed about fertility preservation options and a number of guidelines how fertility 
consultations should be addressed, physicians are still misled by their personal biases when it 
comes to discussing fertility preservation during consultations. We identified the studies from 
information on 
FP 
 
Germany; 2014  149 cancer 
patients aged 18-
45;  questionnaire  
74% had a desire 
to have children 
at the time of 
diagnosis 
60% discussed 
fertility with 
oncologists 
20% discussed 
fertility with 
specialist 
56% male undergone 
sperm 
cryopreservation 
31% female preserved 
fertility: 
4 oocyte 
cryopreservation 
5 ovarian tissue 
cryopreservation 
13 took medication 
[39] 
the UK, Japan, Saudi Arabia, Turkey, Iran and the USA reporting fertility preservation 
practices and factors influencing physician’s decision to discuss fertility preservation with 
their patients (Table 3).  
Only British and American physicians are reported to discuss fertility issues with their 
patients on most occasions [53,54]. However, American physicians tend to have more biases 
based on social, gender and racial factor than medical prognosis compared to the UK 
physicians [53]. In other countries fertility preservation consultations do not occur on regular 
basis and referrals to fertility specialists are even lower [46,55,56]. General tendency noted in 
most studies is that physicians are concerned with patient’s prognosis [49,53], type of cancer 
[46,53] and reluctance to delay the start of treatment [49,57]. Lack of knowledge about 
fertility preservation and time constraints were also among the reasons why fertility 
preservation was not addressed by British, Japanese, Turkish and Iranian physicians (Table 
3).  
The same as with patient surveys, it has to be noted that physicians’ surveys also vary in 
sample sizes and response rates; especially studies from Iran and Turkey have very low 
participant numbers. However, the methodology is more coherent and studies could be 
legitimately compared: postal or online questionnaires are used; attitudes, consultation and 
further referral practises are studied, reasons why fertility preservation issues are not 
discussed are also addressed by most studies. It allows concluding that successful fertility 
preservation programmes are still to be developed worldwide. It will require oncology 
specialists to become aware of the latest achievements in fertility preservation medicine, 
sensitiveness to individual patients’ values and goals and multidisciplinary approach. Kim 
and colleagues suggest to have a highly skilled team consisting of oncologists, fertility 
specialists, embryologists, and mental health professionals [58].  
One more important aspect to be mentioned is the biases physicians possess based on 
patients’ socioeconomic background, age, partnership status, existing children, sexual 
orientation, and in some cases religion. It will have to be addressed in ongoing specialist 
training providing physicians the skills and tools to manage their biases. For instance, 
oncologists in Saudi Arabia have a favourable attitude towards sperm banking for male 
patients but referral numbers are still low [46]. In Iran nearly half oncologists think that 
fertility preservation topic should be brought up by patients themselves [56]. It is interesting 
to note that oncologist’s enthusiasm about fertility preservation options does not generally 
lead to be better physician-patient relationship [59] which brings us back to the point that 
survival might still be primarily concern for the majority of cancer patients.  
Table 3 
Physician practices and factors influencing decisions 
Country; 
Publication year  
Participants; 
Type of survey 
FP consultation 
practises (%) 
Factors influencing 
decision to/not to 
discuss FP (%) 
 
Reference 
UK; 2013 100 oncologists; 
online 
97% usually or 
always discuss 
treatment effect 
on fertility 
67% have 
referred patients 
to fertility 
specialist 
38% provide 
written 
information 
about fertility 
 
93% patient too ill to 
delay treatment 
88% poor prognosis 
72% patient has 
hormonally sensitive 
tumour 
44% patient already 
has children 
32% patient is single 
27% patient could not 
afford FP 
21% patient is 
homosexual 
 
[53] 
UK; 2012 306 surgeons, 
oncologists, 
clinical nurse 
specialists 
working with 
breast cancer 
patients; online 
Average number 
of referrals to 
fertility unit was 
3 patients (range 
0-25) per 
respondent in 
the last 12 
months 
78% patients age 
37,9% final 
tumour/node/metastasis 
status 
37,3% concern that it 
delay chemotherapy 
33,5% whether patient 
already has children 
[49] 
24,7% whether patient 
has partner 
22,6% estrogen 
receptor expression  
20,9% lack of 
knowledge 
19,9% concern that FP 
would compromise the 
treatment success 
 
Japan; 2013  434 breast 
oncologists; 
paper surveys 
sent by mail 
83% positive in 
discussing FP 
42% refer 
patients to 
reproductive 
specialist when 
patients express 
concerns 
 
51% high risk of 
cancer reoccurrence 
45% lack of 
reproductive specialists 
45% time constraints 
[57] 
Saudi Arabia; 
2010  
103 medical, 
radiation and 
surgical 
oncologists 
working with 
male patients; 
self 
administered 
questionnaire 
94% felt that FP 
help patients 
psychologically 
42% routinely 
discuss FP with 
patients 
63% positive 
about discussing 
FP with parents 
of prepubertal 
boys 
39% never refer 
patients to FP 
specialist 
19,5% refer 
patients to 
92% type of cancer 
87% patient’s age 
82% marital status 
84% number of 
existing children 
69% cost of sperm 
cryopreservation 
2,9% religion 
[46] 
fertility 
specialist 
 
Turkey; 2012  25 
haematologists; 
questionnaire  
60% did not 
inform their 
patients about 
FP 
76% did not feel 
they have 
enough 
knowledge about 
FP 
80% expressed 
approval of 
postponing 
treatment for a 
short period to 
accommodate 
FP 
 
Not provided [55] 
Iran; 2011 30 oncologists; 
questionnaire 
46% knew about 
FP techniques 
40% insisted 
that patients 
have to bring FP 
topic themselves 
 
67% believed FP 
should be offered to all 
patients at risk 
[56] 
USA; 2013  185 
hematopoietic 
cell transplant 
physicians; 
online 
55% refer to 
fertility 
specialist 
 
92% patients were 
already infertile 
63% patients were too 
ill to delay transplant 
35% insurance does 
not cover FP 
33% patients cannot 
afford to pay FP 
[60] 
27% time constraints 
16% no sufficient 
knowledge 
15% do not have 
information to give to 
patients about FP 
14% patients do not 
want to discuss FP 
12% there is no FP 
specialist  
 
USA; 2010  249 oncologists 
working with 
female patients; 
online 
95% discuss FP 
5,8% always 
refer to fertility 
specialist 
33,2% usually 
refer to fertility 
specialist 
43,3% rarely 
17,8% never 
30% poor prognosis 
22% need to initiate 
therapy in 1-2 weeks 
10% patient has a child 
already 
8% poor success of FP 
7% patient too young 
to have children 
6% limited knowledge 
of risks 
5% lack of availability 
of FP services 
4% cost is prohibitive 
2% patient is a lesbian 
1% patient is not 
married 
 
[54] 
USA; 2009  613 oncologists 
working with 
46,7% always or 
often referred 
Not provided [61] 
adult patients; 
postal survey 
and online 
survey 
patients who had 
questions about 
fertility to 
fertility 
specialist 
 
 
Practicalities to consider in oncofertility consultation 
Fertility preservation consultation is an additional concern on top of cancer treatment but it is 
becoming generally agreed that addressing fertility issues in cancer care should become a 
standard practice (Table 1). Discussing treatment consequences on sexuality and fertility 
might involve more parties than just patients and physicians. Children have parents who are 
there to represent the best interests of the children, patients in committed relationships might 
want to have their partners involved in decision making, some cultures and faiths might see 
fit to have other family members, friends and/or religious or community leaders involved. Up 
to date there is not much research done on the involvement of other parties in fertility 
preservation decision making. Research focusing on the partners of cancer survivors and their 
concerns regarding fertility is suggested [40] but not accomplished to date. However 
partner’s involvement in fertility consultation is suggested by EUSOMA guidelines [37]. 
Considering the above mentioned concerns, some scholars urge the need to focus on 
oncofertility implications on both societal and individual levels [62]. Important points to 
consider when creating functional oncofertility system are proposed to include the following: 
privacy and confidentiality; consent/assent; safety and efficacy of experimental techniques; 
conflict of interest regarding patient needs and personal/institutional financial incentives; age 
restrictions (minimum and maximum); future use of stored tissue, gametes, and embryos; 
creation of centralized registry of those who preserve their fertility [63]. Decision support 
interventions, like decision counselling or decision coaching, are tools designed to help 
patients to participate in specific and deliberated decision making among health-related 
options. They help patients to recognize the values-sensitive nature of the decision and to 
clarify, either implicitly or explicitly, the value they place on the benefits, harms, and 
scientific uncertainties [64,65]. 
Moreover, it is important to keep in mind that the field of fertility preservation in cancer 
patients, as well as that of infertility treatments, was shaped by medical and non-medical 
factors such as societal attitudes regarding infertile people, having children as means of 
survival and work-force or, what is more common in modern society, seeking fulfilment in 
life [66]. Ethical issues are important aspect of decision-making process. Therefore, we 
would like to suggest that ethical aspects should be included in decision support 
interventions. As well as financial aspects of fertility preservation procedures should not be 
overlooked. Insurance coverage for fertility preservation treatment is one of the most debated 
questions in the USA [7]. Some argue that there is little ethical justification to withhold 
insurance coverage for fertility preservation technologies [16] while reservations can still be 
expressed especially when it comes at tax payers’ expense. Various experts have debated on 
what factors should be targeted to eliminate disparities including socioeconomic status, race, 
biology, access to care, lack of insurance, stage of the disease at the diagnosis [33]. United 
States had a 14% decrease in mortality from cancer in a period between 1991 and 2004 but it 
has not benefited to all segments of the population, as a response ASCO issued a policy 
statement pointing out that low income, lack of insurance and restricted access to care are 
playing a major role in health disparities [67]. In a later report ASCO concluded that 
providing quality care to all patients with cancer, regardless of their racial, socioeconomic, or 
geographical group, is a priority [68].  
Preserving fertility impose significant costs and in case of cancer patients it is not clear if 
cryopreserved material will ever be used for the benefit of the patient. Initial oocyte retrieval 
cost is advertised $6000-12000 plus $2000-5000 for medication (2014-01-31 at Extended 
Fertility Website http://www.extendfertility.com/about/faq.php), annual storage fee with 
Extended Fertility in Massachusetts is reported to be $440 [69]. In Germany patients have to 
cover the costs of fertility preservation themselves: cryopreservation of fertile eggs costs 
about 3000 Euros, sperm cryopreservation about 350 Euros, storage of either about 250 Euros 
a year [39]. The cost of fertility treatment led to proposal of guidelines where two the most 
important inclusion criteria for experimental gonadal tissue cryopreservation are urged to be a 
high risk of future infertility and a high likelihood of long-term survival because 
commercialisation of medical interventions can lead to irrational investments [70]. The 
annual storage fee for cryopreserved materials could easily become a source of psychological 
pressure and financial burden rather than future opportunity [71].  
Therefore we would like to suggest that more attention has to be paid to designing decisional 
support services for cancer patients. Informing patients (their parents or guardians) how 
cancer treatment could affect future fertility in age, disease and gender specific way is 
already a standard imposed by many professional guidelines (Table 1). Providing information 
about fertility preservation options while referring patient to the specialist when patient is 
interested in fertility preservation is also practice supported by many physicians (Table 3). 
However, high quality patient care does not end with referral to another specialist. Other 
types of support have high potential to benefit cancer patients too. We provide more details in 
Table 4 and suggest that a high quality cancer care should includes multiple steps in 
sometimes very short period of time which will require close and efficient collaboration 
among a wide range of specialists. Assisting patients to understand the implications of their 
condition to their future life and choosing fertility preservation options accordingly we 
consider the core part of decisional counselling services. Furthermore, we suggest focusing 
on patient’s values based on their personal philosophy and view of life, spirituality and 
sometimes emotions ignited by cancer diagnosis which would shape their goals and 
consequentially decisions leading to practicalities such as national legislation of fertility 
preservation procedures and financial implications.  
Table 4 
Decisional support types when counselling cancer patients about fertility preservation 
Support type Key features 
 
1. Understanding 
medical and 
clinical reality 
Disease impact on future life: 
-what functions will be impaired 
- what are treatment side effects 
- what are survival rates 
- what care will be needed during treatment and after it is finished 
 
2. Informing 
about fertility 
preservation 
options 
Established and experimental options: 
- local availability  
- success rates 
- risks and benefits 
- costs  
- who will cover the costs: public health system, private insurance, 
charities, private funds 
 
3. Identifying 
patient’s 
expectations 
Personal values and goals in the light of the prognosis: 
- what treatment is acceptable 
- what are the tenets of patient’s personal philosophy 
- how much risk (survival versus fertility) patient is ready to accept 
- how  important is fertility, survival, quality of life 
 
4. Legal 
guidance* 
Local, regional, national, federal legislation on fertility preservation 
methods 
 
5. Psychological 
and emotional 
support* 
 
Fear, anxiety, present and anticipated guilt 
6. Spiritual 
and/or religious 
guidance* 
Are there religious preferences? 
-what FP methods are acceptable 
- what FP would mean 
 
7. Financial 
counselling* 
Planning finances during cancer treatment: 
- reduced capacity to work 
- lower income during the course of treatment 
- personal care expenses 
- cancer treatment expenses not covered by insurance 
- childcare (if any) expenses 
- fertility preservation (treatment and storage) expenses 
 
* These counselling services could be optional, depending on the need and relevance in a 
specific situation 
Conclusions 
In most cases the main cause of infertility in cancer patients is treatment, not the disease. 
Therefore, consultation for fertility preservation should take place before cancer treatment. 
The established and experimental methods to preserve fertility are now available in many 
centres and cancer patients demonstrate interest in fertility preservation. Nonetheless, a 
significant number of patients worldwide are not given information about the detrimental 
effects on fertility of cancer treatments and the possibilities to preserve fertility. Physicians 
are still misled by their personal judgmental biases on whom to offer fertility preservation 
consultation. Lack of time and knowledge about existing options, poor prognosis, and delay 
in treatment, patient’s age, partnership status, existing children and socioeconomic situation 
are identified as the main barriers to initiate the consultation. Moreover, fertility preservation 
consultation is not limited to medical aspects. Patient’s needs, values and priorities have to be 
addressed within the context of medical necessities, realistic survival forecast, socio-cultural 
environment and availability of resources. We suggest a framework for improving decisional 
support services for cancer patients who would like to consider fertility preservation options. 
Our proposal is based on helping patients to clarify the implications of their condition for the 
future life, identify the values on which their base their personal philosophy of life and 
address practical aspects of the preferred decision on fertility preservation procedures.  
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